Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Ain Shams University
60 participants
May 1, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are: 1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD? 2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD? Researchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.
Eligibility
Inclusion Criteria2
- Adult patients aged eighteen or older.
- Patients with advanced chronic kidney disease (i.e., eGFR \< 20 mL/min/1.73m2)not on dialysis
Exclusion Criteria7
- Autosomal dominant polycystic kidney disease (ADPKD).
- Type 1 diabetes mellitus
- Patients on SGLT2 inhibitors.
- History of ketoacidosis in the last 3 months.
- Known hypersensitivity to SGLT2 inhibitors.
- Known hepatic impairment.
- Pregnant or breastfeeding females.
Interventions
Dapagliflozin 10 mg will be added in addition to standard of care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06982079